Team

Dr. Klaus Breiner

Partner
read more

Dr. Klaus Breiner

Partner

Managing Partner at BB Biotech Ventures since 2004. Co-founder and, from 2008 till 2016, Executive Chairman of Vaximm, a Swiss-German immuno-oncology company. Prior to joining Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Glycart, Intercell, Pevion, Vaximm and AM-Pharma. PhD Molecular Biologist & Chemist.

Dr. Dominik Escher

Partner
read more

Dr. Dominik Escher

Partner

Former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody drugs. Alcon acquired ESBATech for USD 589 million in 2009, a landmark exit for its investors. Subsequently until 2016 Vice President of Alcon Research & Development and at Novartis Member of the Global Ophthalmology Leadership and Global Biologics Leadership. Since 2002, on the Board of the Swiss Biotech Association and President since 2013. PhD Molecular Biologist.

Dr. Martin Münchbach

Partner
read more

Dr. Martin Münchbach

Partner

Managing Partner at BB Biotech Ventures since 2004. He has been an active venture capitalist since the late 90’s, investing in life science companies across all stages and types. Prior to joining Bellevue Group, Investment Manager at BioMed, HBM and NMT. Martin’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan and Glycart. PhD Protein Chemist & Biochemist.

Dr. Thomas Hecht

Advisory Board
read more

Dr. Thomas Hecht

Advisory Board

Past and present Chairman or Director at several biopharmaceutical companies, including ESBATech, Cytos, Affimed, Cellmedica, Suppremol, Humabs, and Vaximm; senior veteran from Amgen Europe (Clinical, Med affairs & Marketing).

Prof. Dr. Roger Nitsch

Advisory Board
read more

Prof. Dr. Roger Nitsch

Advisory Board

University of Zurich, key opinion leader in neurodegenerative diseases; directs the Institute for Regenerative Medicine; Co-founder and Chairman of Neurimmune, developer of aducanumab, now in partnership with Biogen (Alzheimer’s disease).

Prof. Dr. Bernd Seizinger

Advisory Board
read more

Prof. Dr. Bernd Seizinger

Advisory Board

Former President & CEO of GPC Biotech, a NASDAQ listed oncology company. He brought the company from pre-clinical to phase 3 clinical oncology.
VP Oncology drug discovery BMS, MGH and Harvard Medical School faculty member. 

Dr. Mathieu Simon

Advisory Board
read more

Dr. Mathieu Simon

Advisory Board

Former EVP, COO and board director of Cellectis, a premier CAR T-cell and DNA editing company, NASDAQ listed (CLLS). Prior to that, Head of Global Pharmaceutical Operations at Pierre Fabre and in senior corporate and regional roles at Wyeth (US and Europe). Medical Doctor.

Prof. Dr. Dr. Klaus Strein

Advisory Board
read more

Prof. Dr. Dr. Klaus Strein

Advisory Board

Board Director at BB Biotech AG; Co-founder, Chairman and CEO of Engmab, sold to Celgene in a landmark exit in 2016; previously at Roche Head of small & large molecule research and prior to that Head of Pharma R&D at Boehringer Mannheim.

Dallas Webb

Advisory Board
read more

Dallas Webb

Advisory Board

Portfolio Manager at BB Biotech AG in New York since 2006, prior healthcare equity analyst positions with Stanford, Sterling, and Adam Harkness & Hill. Dallas holds an MBA and a BS in Microbiology.

Luigi Costa

Entrepreneur in residence
read more

Luigi Costa

Entrepreneur in residence

Previously CEO of Nordic Nanovector, a Norwegian oncology/hematology company, he IPOed in 2015 at the Oslo stock exchange. Previously at Eli Lilly and in senior management positions with Amgen and Onyx in regional and commercial leadership roles.

Ben Morgan

Director
read more

Ben Morgan

Director

Partner of the Corporate Group of Carey Olsen in Guernsey. Mr. Morgan qualified as an English solicitor in 1992 and practiced in London for a number of years before returning to Guernsey in 1997, having worked for one of the leading law firms, Norton Rose. He joined Olsens (which became Carey Olsen) in 1999, where he headed the Corporate Group before its merger with Carey Olsen. He currently holds a number of directorships with other fund management companies and funds. Mr. Morgan has been a Director of BB Biotech Ventures GP (Guernsey) Limited since 2005.